HBM Healthcare Investments AG
/ Key word(s): AGMEGM
At today’s ordinary Shareholders’ Meeting of HBM Healthcare Investments Ltd the shareholders approved all proposals submitted by the Board of Directors. The Chairman of the Board of Directors Hans Peter Hasler and the existing board members Dr Rudolf Lanz, Mario G. Giuliani, Dr Stella X. Xu and Dr Elaine V. Jones were re-elected for a further one year term. The existing members of the Compensaiton Committee Mario G. Giuliani, Dr Stella X. Xu and Dr Elaine E. Jones were also re-elected for a further one year term. Furthermore, the shareholders approved the proposed compensation to the Board of Directors and to the Management. Further, the Shareholders’ Meeting approved a par value repayment of CHF 7.50 per share. The cash payment will be made on 9 August 2024. The registered shares with entitlement to the distribution will be traded for the last time on 6 August 2024 (from 7 August 2024 without, ex-date). The presentation shown at the Shareholder’s Meeting 2024 can be accessed on the company's website at hbmhealthcare.com/en/investors/shareholders-meeting. Contact
End of Media Release |
Language: | English |
Company: | HBM Healthcare Investments AG |
Bundesplatz 1 | |
6300 Zug | |
Switzerland | |
Phone: | +41438887171 |
Fax: | +41438887172 |
E-mail: | info@hbmhealthcare.com |
Internet: | https://www.hbmhealthcare.com |
ISIN: | CH0012627250 |
Valor: | 1262725 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1926963 |
End of News | EQS News Service |
|
1926963 17.06.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.